The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Thursday preview: US jobless claims, AstraZeneca in the spotlight

Wed, 10th Feb 2021 18:52

(Sharecast News) - The economic calendar on Thursday will be exceedingly light with a reading on weekly US unemployment claims the only event that might easily move markets.



Consensus is expecting but a slight drop in the number of initial jobless claims from 779,000 for the week before to 769,000.

A speech from European Central Bank vice-president, Luis De Guindos, will also be worth monitoring.

No major economic releases are scheduled in the UK.

Further afield, rate-setters in Manila are due to meet to decide on policy.



For AstraZeneca's fourth quarter, UBS analyst Michael Leuchten has penciled sales of $7.22bn, putting him slightly ahead of the consensus which is at $7.16bn.

Core operating profits on the other hand were pegged to come in at $1.94bn (consensus: $2.02bn) for earnings per share of $1.04 (consensus: $1.09).

"Top-line momentum remains key for investors," he said, adding that he expected investors to focus their questions on the outfit's business in China, which accounts for approximately a fifth of its sales.

The analyst also broke down his sales forecasts for AstraZeneca's key treatments: Tagrisso ($1.15bn), Lynparza ($483m), Imfinzi ($532m) and Calquence ($157m).

Going forwards, Leuchten expected AstraZeneca would guide towards single-digit topline growth - excluding vaccines - and for mid-to-high teens growth in earnings per share, with the latter not including gains from the spin-out of Viela.

Thursday 11 February

INTERIMS

MJ Gleeson

INTERIM EX-DIVIDEND DATE

Hargreaves Lansdown, Henderson Smaller Companies Inv Trust, PZ Cussons, The Mission Group

QUARTERLY EX-DIVIDEND DATE

BMO Commercial Property Trust Limited, Chenavari Toro Income Fund Limited NPV, Custodian Reit , ICG Enterprise Trust, The Renewables Infrastructure Group Limited

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Continuing Claims (US) (13:30)

Initial Jobless Claims (US) (13:30)

Q4

AstraZeneca

GMS

Coral Products, Tesco

FINALS

AstraZeneca, Coca-Cola European Partners (DI), Coca-Cola HBC AG (CDI), Relx plc, Yamana Gold Inc. NPV (CDI)

SPECIAL EX-DIVIDEND DATE

Anglo Asian Mining

EGMS

Glanbia, Law Debenture Corp.

AGMS

Euromoney Institutional Investor

UK ECONOMIC ANNOUNCEMENTS

RICS Housing Market Survey (00:01)

FINAL DIVIDEND PAYMENT DATE

Hargreave Hale AIM VCT , Sage Group, Unicorn AIM VCT

FINAL EX-DIVIDEND DATE

Aberforth Smaller Companies Trust, Avon Rubber, Blackrock Income And Growth Investment Trust, Northamber

Related Shares

More News
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.